The American pharmaceutical giant Johnson & Johnson has applied for authorization for its vaccine against Covid-19 in the European Union, the European Medicines Agency announced on Tuesday, adding that a decision was expected in March.
This single-injection vaccine would be the fourth to be approved in the European Union if given the green light from the Amsterdam-based agency.
“The EMA has received a marketing authorization application for a vaccine against Covid-19 developed by Janssen-Cilag International NV,” the agency said, referring to the European subsidiary of Johnson & Johnson.
European experts “could issue an opinion in mid-March 2021, provided that the company’s data on the efficacy, safety and quality of the vaccine is sufficiently complete and convincing,” according to the EMA.
Johnson & Johnson’s vaccine has been under continuous evaluation by the EMA since December 1.
The three vaccines authorized to date on the European market are those of AstraZeneca, Pfizer / BioNTech and Moderna.
The European Commission has ordered 200 million doses of the vaccine from Johnson & Johnson, with an option for 200 million more. One hundred million doses must be delivered by June if the vaccine is approved.